Curaleaf Holdings' QMID enters Australia's Class IIb medical device register
The ARTG's Sept. 15 entry names Jupiter Research as manufacturer; Curaleaf also reports a Sept. 17 New Zealand WAND notification.
Theo Marchetti
Australia's Therapeutic Goods Administration added an ambulatory therapeutic agent vaporizer to its medical device register on Sept. 15, classifying it as Class IIb. Curaleaf Holdings, Inc. TSECURA OTCMKTSCURLF identified the device on Oct. 2 as its Que Medical Inhalation Device, or QMID, and said it is now available in seven countries.
Curaleaf shares closed at C$14.66 in Toronto at 4 p.m. EDT on Oct. 1, according to the TSECURA quote page. The Oct. 1 close cannot show a share-price reaction to Curaleaf's Oct. 2 announcement.
The Australian Register of Therapeutic Goods entry, ID 531287, lists Vicki Partridge Pty Ltd as the sponsor and Jupiter Research LLC as the manufacturer. The register calls the product a "therapeutic agent vaporizer, ambulatory"; Curaleaf's release supplies the QMID brand name and says the device is intended to deliver cannabis extracts by inhalation.
New Zealand Uses a Notification System
Curaleaf also said QMID was entered in New Zealand's Web Assisted Notification of Devices database on Sept. 17, making it available to prescribers there. Medsafe says devices must be notified to WAND for legal supply in New Zealand. WAND records a sponsor notification; Australia's register assigns Class IIb status.
Medsafe restricts database access to device sponsors, so Curaleaf's Sept. 17 notification cannot be checked against a public WAND entry. The company's Oct. 2 release names Vicki Partridge as sponsor in both markets but gives no New Zealand device record number.
Curaleaf says the reusable QMID hardware powers aerosolization of prescribed cannabis-based medicine and works only with approved cartridges. The company says the design supports consistent dosing, while its release reports no patient outcome data. The Australian entry classifies a medical device and does not identify a registered cannabis medicine.
"Together with Jupiter, we have invested heavily to meet that bar, and we intend to bring the same standard to more patients wherever the regulatory pathway allows, starting with New Zealand," Curaleaf International chief executive Juan Martinez said in the Oct. 2 release.
Curaleaf described an Australian QMID launch in November 2025, saying then that the device could be offered to eligible patients on prescription. The September 2026 register entry is a later regulatory step. Curaleaf says QMID gained European Class IIa medical device certification in May 2025, before the separate Australian Class IIb listing.
The Oct. 2 release gives no Australian unit-sales count, device price or revenue forecast. It also does not name the seven countries where it says QMID is available or provide a first-sale date for either newly listed market.
Curaleaf's U.S. cannabis operations face a separate regulatory calendar: the DEA's marijuana rescheduling hearing remains stayed after a Sept. 29 order.
Read more: DEA judge stays marijuana rescheduling hearing over GAO report motion
Australia's register dates its entry Sept. 15, and Curaleaf dates the New Zealand notification Sept. 17. Its Oct. 2 announcement sets no next sales or regulatory decision date.
